Press Release Rachel Swansburg 11/10/25 Press Release Rachel Swansburg 11/10/25 City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases Read More Press Release Rachel Swansburg 5/27/25 Press Release Rachel Swansburg 5/27/25 Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Read More Press Release Rachel Swansburg 4/17/25 Press Release Rachel Swansburg 4/17/25 City Therapeutics Expands Executive Team and Board of Directors Read More Press Release IT Admin 1/10/25 Press Release IT Admin 1/10/25 City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Read More Press Release IT Admin 1/7/25 Press Release IT Admin 1/7/25 City Therapeutics Appoints Andy Orth as Chief Executive Officer Read More Press Release Matthew Zola 10/8/24 Press Release Matthew Zola 10/8/24 City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine Read More
Press Release Rachel Swansburg 11/10/25 Press Release Rachel Swansburg 11/10/25 City Therapeutics Announces Submission of Clinical Trial Application for CITY-FXI, an Investigational RNAi Therapeutic for the Treatment of Thromboembolic Diseases Read More
Press Release Rachel Swansburg 5/27/25 Press Release Rachel Swansburg 5/27/25 Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies Read More
Press Release Rachel Swansburg 4/17/25 Press Release Rachel Swansburg 4/17/25 City Therapeutics Expands Executive Team and Board of Directors Read More
Press Release IT Admin 1/10/25 Press Release IT Admin 1/10/25 City Therapeutics Announces Strategic Collaboration with Bausch + Lomb to Develop a Novel RNAi-Based Treatment for Geographic Atrophy Read More
Press Release IT Admin 1/7/25 Press Release IT Admin 1/7/25 City Therapeutics Appoints Andy Orth as Chief Executive Officer Read More
Press Release Matthew Zola 10/8/24 Press Release Matthew Zola 10/8/24 City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine Read More
